Pipeline / 03 · Neuro & Oncology

Brain Mapping Platform

AI-assisted neuro-biomarker discovery through integrated proteomics and genomics at Beijing Tiantan Hospital.

Premise

The problem we are solving.

Neurological disease is where our diagnostic tools fail most consistently. Brain tissue is inaccessible, biomarkers are diffuse, and disease progression is silent until it is already late. Mapping the brain's molecular landscape — at scale, with AI interpretation — changes what is detectable, and when.

In partnership with Beijing Tiantan Hospital and BGI Beijing, MACRO HRD's Brain Mapping platform integrates proteomic and genomic data streams with AI-driven biomarker discovery, building the foundation for earlier detection across neurodegenerative disease and glioblastoma.

Approach

How we tackle it.

The Brain Mapping platform integrates three signal streams: tissue-resident proteomics from neurosurgical specimens (made possible by the Tiantan partnership, one of the highest-volume neurosurgical centers globally), population-scale genomics from BGI Beijing, and longitudinal clinical data from partner sites across the Brain Mapping consortium.

GEDM-3DQ provides the AI interpretation layer — identifying biomarker signatures that distinguish disease subtypes, predict progression, and stratify patients for cohort-appropriate therapy. Findings flow into the Huntington's Disease, MSC Neuroregeneration, and Glioblastoma programs as a shared molecular substrate.

Capabilities

What makes this real.

01
Tissue-proximal proteomics
Direct access to neurosurgical specimens from Beijing Tiantan Hospital — biomarker discovery from the disease site itself, not from indirect peripheral signals.
02
Population-scale genomics
BGI Beijing partnership provides genomic context — allowing biomarkers identified in tissue to be validated against broad genetic backgrounds.
03
AI-driven signature discovery
GEDM-3DQ analyzes integrated multi-omics signal streams to identify disease-specific molecular signatures and subtype stratification.
04
Cross-program substrate
Findings flow directly into Huntington's, MSC Neuroregeneration, and Glioblastoma programs — the platform is shared infrastructure, not a standalone effort.
GLOBAL SCIENTIFIC COLLABORATION NETWORK Eight institutions, four continents. Ragon Institute of MGH, MIT and Harvard BOSTON, USA Universiteit Antwerpen Vaccinopolis ANTWERP, BELGIUM Tiantan Hospital Neurosurgical research BEIJING, CHINA Tsinghua University Translational medicine BEIJING, CHINA Peking University Biomarker discovery BEIJING, CHINA BGI Genomic data integration BEIJING, CHINA U. KwaZulu-Natal African genomics DURBAN, SOUTH AFRICA Mae Fah Luang U. Translational neurotherapeutics CHIANG RAI, THAILAND
Global scientific collaboration network supporting the Brain Mapping program — Tiantan Hospital (Beijing), BGI Beijing, Tsinghua University, Peking University, and the Ragon Institute — integrating proteomic, genomic, and imaging data across populations.
Where It Connects

Part of an integrated platform.

03 · Neuro & Oncology
Huntington's Disease Program
Precision neurotherapeutic strategies and molecular disease modeling for a monogenic disease with no current cure.
03 · Neuro & Oncology
GBM Immunotherapy Program
An immune-based therapeutic approach to glioblastoma — engineered to cross the blood-brain barrier and activate anti-tumor response in the CNS.
03 · Neuro & Oncology
MSC Neuroregeneration Program
Mesenchymal stem cell therapies for neurodegenerative disease — secreted bioactive factors for repair and anti-inflammation.
01 · Platforms
GEDM-3DQ Decision Engine
Gradient Equilibrium Decision Modeling in 3-Dimensional Quadrant — the AI spine of every MACRO HRD program.
⸻ Continue the platform

“The brain reveals itself slowly. We have built the instruments to listen carefully.”

See all ventures → Engage with MACRO HRD